This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (25) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Peele, P. B. Articles by Ravdin, P. M. Search for Related Content PubMed PubMed Citation Articles by Peele, P. B. Articles by Ravdin, P. M. Social Bookmarking                         What's this?

Decreased Use of Adjuvant Breast Cancer Therapy in a Randomized Controlled Trial of a Decision Aid with Individualized Risk Information

Department of Health Policy & Management, Graduate School of Public Health, University of Pittsburgh, peele{at}pitt.edu

Laura A. Siminoff, PhD

Department of Bioethics, School of Medicine, Case Western Reserve University, Cleveland OH

Ying Xu, MS

Department of Health Policy & Management, Graduate School of Public Health, University of Pittsburgh

Peter M. Ravdin, MD

Department of Medicine, University of Texas Health Science Center, San Antonio

Objective. Oncology patients often seek involvement in their medical consultations. Such involvement is endorsed by most health care providers and mirrored in practice guidelines. However, oncologists exhibit great variation in how they provide patients with disease-relevant information, and many remain reluctant to do so at all. The authors examined the impact of a patient-specific decision aid on women’s decisions about adjuvant therapy for breast cancer. Method. 386 women with breast cancer were randomized to receive either an informational pamphlet about adjuvant therapy (usual care) or a patient-specific, evidence-based decision aid about adjuvant therapy. The authors compared rates of adjuvant therapy between the groups controlling for age, education, marital status, race, tumor severity, and practice type of their physician (university-based or community-based). Results. Among women with low tumor severity, only 58% (35/60) of women in the decision aid group chose adjuvant therapy, compared to 87% (33/38) of their counterparts in usual care (P < 0.01). Conclusions. This study illustrates the important impact of medical decision aids on treatment choices, particularly for patients for whom treatment has little benefit. In the case of adjuvant therapy for breast cancer, providing individualized, evidence-based risk information for shared decision making resulted in fewer women with low tumor severity choosing adjuvant treatment.

Key Words: decision aid • cancer • decision making • information preferences

Medical Decision Making, Vol. 25, No. 3, 301-307 (2005)
DOI: 10.1177/0272989X05276851


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. W. Kurian, B. M. Sigal, and S. K. Plevritis Survival Analysis of Cancer Risk Reduction Strategies for BRCA1/2 Mutation Carriers J. Clin. Oncol., January 10, 2010; 28(2): 222 - 231. [Abstract] [Full Text] [PDF]

				A. J. Vickers, E. B. Elkin, P. B. Peele, M. Dickler, and L. A. Siminoff Long-Term Health Outcomes of a Decision Aid: Data from a Randomized Trial of Adjuvant! in Women with Localized Breast Cancer Med Decis Making, July 1, 2009; 29(4): 461 - 467. [Abstract] [PDF]

				M. Ouwens, M. Hulscher, R. Hermens, M. Faber, H. Marres, H. Wollersheim, and R. Grol Implementation of integrated care for patients with cancer: a systematic review of interventions and effects Int. J. Qual. Health Care, April 1, 2009; 21(2): 137 - 144. [Abstract] [Full Text] [PDF]

				M. A. O'Brien, T. J. Whelan, M. Villasis-Keever, A. Gafni, C. Charles, R. Roberts, S. Schiff, and W. Cai Are Cancer-Related Decision Aids Effective? A Systematic Review and Meta-Analysis J. Clin. Oncol., February 20, 2009; 27(6): 974 - 985. [Abstract] [Full Text] [PDF]

				E. M. Ozanne, D. Braithwaite, K. Sepucha, D. Moore, L. Esserman, and J. Belkora Sensitivity to Input Variability of the Adjuvant! Online Breast Cancer Prognostic Model J. Clin. Oncol., January 10, 2009; 27(2): 214 - 219. [Abstract] [Full Text] [PDF]

				S. Leatherman and L. Warrick Effectiveness of Decision Aids: A Review of the Evidence Med Care Res Rev, December 1, 2008; 65(6_suppl): 79S - 116S. [Abstract] [PDF]

				D. F Munday and E J. Maher Informed consent and palliative chemotherapy BMJ, July 31, 2008; 337(jul31_3): a868 - a868. [Full Text]

				S. E. Harrington and T. J. Smith The Role of Chemotherapy at the End of Life: "When Is Enough, Enough?" JAMA, June 11, 2008; 299(22): 2667 - 2678. [Abstract] [Full Text] [PDF]

				J. J. van Tol-Geerdink, P. F.M. Stalmeier, E. N.J.T. van Lin, E. C. Schimmel, H. Huizenga, W. A.J. van Daal, and J.-W. Leer Do Patients With Localized Prostate Cancer Treatment Really Want More Aggressive Treatment? J. Clin. Oncol., October 1, 2006; 24(28): 4581 - 4586. [Abstract] [Full Text] [PDF]

				R. Matsuyama, S. Reddy, and T. J. Smith Why Do Patients Choose Chemotherapy Near the End of Life? A Review of the Perspective of Those Facing Death From Cancer J. Clin. Oncol., July 20, 2006; 24(21): 3490 - 3496. [Abstract] [Full Text] [PDF]